Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions

September 16th 2022, 8:49pm


Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

CAR T-Cell Therapy a Story of Opportunities and Challenges in MM

September 12th 2022, 7:30pm


Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.

Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?

September 9th 2022, 4:00pm


For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival

How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

September 5th 2022, 4:15pm


Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory

September 2nd 2022, 7:45pm


Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years

August 27th 2022, 8:30pm


Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care

August 19th 2022, 9:36pm


This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).

QOL Tool Valuable in Identifying Patients’ Chief Concerns

August 12th 2022, 3:53pm


A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

August 10th 2022, 3:35pm


Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.

Rare MM Case Underscores Need to Consider Differential Diagnoses

August 6th 2022, 4:05pm


In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.